{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T00:13:28Z","timestamp":1793664808527,"version":"4.5.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T00:00:00Z","timestamp":1695686400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T00:00:00Z","timestamp":1695686400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"National High Level Hospital Clinical Research Funding","award":["2022-PUMCH-A-041"],"award-info":[{"award-number":["2022-PUMCH-A-041"]}]},{"name":"National High Level Hospital Clinical Research Funding","award":["2022-PUMCH-C-006\uff0c2022-PUMCH-B-013"],"award-info":[{"award-number":["2022-PUMCH-C-006\uff0c2022-PUMCH-B-013"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82071839, 82271848"],"award-info":[{"award-number":["82071839, 82271848"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"CAMS Innovation Fund for Medical Sciences","award":["CIFMS 2021-1-I2M-003, 2022-I2M-C&T-B-005"],"award-info":[{"award-number":["CIFMS 2021-1-I2M-003, 2022-I2M-C&T-B-005"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-023-01186-y","type":"journal-article","created":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T14:02:06Z","timestamp":1695736926000},"page":"4787-4795","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["B cell repopulation trajectory after rituximab treatment in autoimmune diseases: a longitudinal observational study"],"prefix":"10.1007","volume":"23","author":[{"given":"Yuxue","family":"Nie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingna","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunjiao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Can","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinping","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengtao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofeng","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linyi","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,26]]},"reference":[{"key":"1186_CR1","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1146\/annurev-cellbio-100617-062518","volume":"35","author":"A Getahun","year":"2019","unstructured":"Getahun A, Cambier JC. Non-antibody-secreting functions of B cells and their contribution to autoimmune disease. Annu Rev Cell Dev Biol. 2019;35:337\u201356. https:\/\/doi.org\/10.1146\/annurev-cellbio-100617-062518.","journal-title":"Annu Rev Cell Dev Biol"},{"key":"1186_CR2","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s12016-020-08820-7","volume":"62","author":"Y Nie","year":"2022","unstructured":"Nie Y, Zhao L, Zhang X. B cell aberrance in lupus: the ringleader and the solution. Clin Rev Allergy Immunol. 2022;62:301\u201323. https:\/\/doi.org\/10.1007\/s12016-020-08820-7.","journal-title":"Clin Rev Allergy Immunol"},{"key":"1186_CR3","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/s41573-020-00092-2","volume":"20","author":"DSW Lee","year":"2021","unstructured":"Lee DSW, Rojas OL, Gommerman JL. B cell depletion therapies in autoimmune disease: advances and mechanistic insights. Nat Rev Drug Discov. 2021;20:179\u201399. https:\/\/doi.org\/10.1038\/s41573-020-00092-2.","journal-title":"Nat Rev Drug Discov"},{"key":"1186_CR4","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1136\/annrheumdis-2014-206605","volume":"74","author":"MN Carruthers","year":"2015","unstructured":"Carruthers MN, Topazian MD, Khosroshahi A, Witzig TE, Wallace ZS, Hart PA, Deshpande V, Smyrk TC, Chari S, Stone JH. Rituximab for IgG4-related disease: a prospective, open-label trial. Ann Rheum Dis. 2015;74:1171\u20137. https:\/\/doi.org\/10.1136\/annrheumdis-2014-206605.","journal-title":"Ann Rheum Dis"},{"key":"1186_CR5","doi-asserted-by":"publisher","first-page":"3586","DOI":"10.1093\/ndt\/gfq256","volume":"25","author":"F Catapano","year":"2010","unstructured":"Catapano F, Chaudhry AN, Jones RB, Smith KGC, Jayne DW. Long-term efficacy and safety of rituximab in refractory and relapsing systemic lupus erythematosus. Nephrol Dial Transplant. 2010;25:3586\u201392. https:\/\/doi.org\/10.1093\/ndt\/gfq256.","journal-title":"Nephrol Dial Transplant"},{"key":"1186_CR6","doi-asserted-by":"publisher","first-page":"731122","DOI":"10.3389\/fphar.2021.731122","volume":"12","author":"YH Chen","year":"2021","unstructured":"Chen YH, Wang XY, Jin X, Yang Z, Xu J. Rituximab therapy for primary Sj\u00f6gren\u2019s syndrome. Front Pharmacol. 2021;12:731122. https:\/\/doi.org\/10.3389\/fphar.2021.731122.","journal-title":"Front Pharmacol"},{"key":"1186_CR7","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1093\/rheumatology\/key450","volume":"58","author":"V Leclair","year":"2019","unstructured":"Leclair V, Galindo-Feria AS, Dastmalchi M, Holmqvist M, Lundberg IE. Efficacy and safety of rituximab in anti-synthetase antibody positive and negative subjects with idiopathic inflammatory myopathy: a registry-based study. Rheumatology (Oxford). 2019;58:1214\u201320. https:\/\/doi.org\/10.1093\/rheumatology\/key450.","journal-title":"Rheumatology (Oxford)"},{"key":"1186_CR8","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1681\/ASN.2014010046","volume":"26","author":"D Geetha","year":"2015","unstructured":"Geetha D, Specks U, Stone JH, Merkel PA, Seo P, Spiera R, Langford CA, Hoffman GS, Kallenberg CGM, St Clair EW, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement. J Am Soc Nephrol. 2015;26:976\u201385. https:\/\/doi.org\/10.1681\/ASN.2014010046.","journal-title":"J Am Soc Nephrol"},{"key":"1186_CR9","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1136\/annrheumdis-2019-216863","volume":"79","author":"RM Smith","year":"2020","unstructured":"Smith RM, Jones RB, Specks U, Bond S, Nodale M, Aljayyousi R, Andrews J, Bruchfeld A, Camilleri B, Carette S, et al. Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis. Ann Rheum Dis. 2020;79:1243\u20139. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216863.","journal-title":"Ann Rheum Dis"},{"key":"1186_CR10","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/S0140-6736(20)32341-2","volume":"397","author":"F Humby","year":"2021","unstructured":"Humby F, Durez P, Buch MH, Lewis MJ, Rizvi H, Rivellese F, Nerviani A, Giorli G, Mahto A, Montecucco C, et al. Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial. Lancet. 2021;397:305\u201317. https:\/\/doi.org\/10.1016\/S0140-6736(20)32341-2.","journal-title":"Lancet"},{"key":"1186_CR11","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1093\/rheumatology\/ker176","volume":"50","author":"H Chen","year":"2011","unstructured":"Chen H, Zheng W, Su J, Xu D, Wang Q, Leng X, Zhang W, Li M, Tang F, Zhang X, et al. Low-dose rituximab therapy for refractory thrombocytopenia in patients with systemic lupus erythematosus\u2013a prospective pilot study. Rheumatology (Oxford). 2011;50:1640\u20134. https:\/\/doi.org\/10.1093\/rheumatology\/ker176.","journal-title":"Rheumatology (Oxford)"},{"key":"1186_CR12","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1007\/s00296-020-04668-4","volume":"40","author":"O Ilizaliturri-Guerra","year":"2020","unstructured":"Ilizaliturri-Guerra O, Uriarte-Botello R, Pineda-Sic R\u00c1, Serna-Pe\u00f1a G, Garza-Elizondo MA, Galarza-Delgado D\u00c1, Leal-Bramasco AS, Elizondo-Sol\u00eds CV, Santoyo-Fexas L, Villarreal-Alarc\u00f3n M\u00c1. Low-dose rituximab therapy in steroid-refractory thrombocytopenia due to systemic lupus erythematosus. Rheumatol Int. 2020;40:1717\u201324. https:\/\/doi.org\/10.1007\/s00296-020-04668-4.","journal-title":"Rheumatol Int"},{"key":"1186_CR13","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1136\/annrheumdis-2017-212878","volume":"77","author":"P Charles","year":"2018","unstructured":"Charles P, Terrier B, Perrodeau \u00c9, Cohen P, Faguer S, Huart A, Hamidou M, Agard C, Bonnotte B, Samson M, et al. Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2). Ann Rheum Dis. 2018;77:1143\u20139. https:\/\/doi.org\/10.1136\/annrheumdis-2017-212878.","journal-title":"Ann Rheum Dis"},{"key":"1186_CR14","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1136\/ard.2007.083162","volume":"67","author":"D Albert","year":"2008","unstructured":"Albert D, Dunham J, Khan S, Stansberry J, Kolasinski S, Tsai D, Pullman-Mooar S, Barnack F, Striebich C, Looney RJ, et al. Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus. Ann Rheum Dis. 2008;67:1724\u201331. https:\/\/doi.org\/10.1136\/ard.2007.083162.","journal-title":"Ann Rheum Dis"},{"key":"1186_CR15","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.clim.2007.11.012","volume":"126","author":"JA Sutter","year":"2008","unstructured":"Sutter JA, Kwan-Morley J, Dunham J, Du Y-Z, Kamoun M, Albert D, Eisenberg RA, Luning Prak ET. A longitudinal analysis of SLE patients treated with rituximab (anti-CD20): factors associated with B lymphocyte recovery. Clin Immunol. 2008;126:282\u201390. https:\/\/doi.org\/10.1016\/j.clim.2007.11.012.","journal-title":"Clin Immunol"},{"key":"1186_CR16","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1002\/art.22019","volume":"54","author":"P Roll","year":"2006","unstructured":"Roll P, Palanichamy A, Kneitz C, Dorner T, Tony H-P. Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis. Arthritis Rheum. 2006;54:2377\u201386. https:\/\/doi.org\/10.1002\/art.22019.","journal-title":"Arthritis Rheum"},{"key":"1186_CR17","doi-asserted-by":"publisher","first-page":"848","DOI":"10.18632\/aging.100894","volume":"8","author":"L Qin","year":"2016","unstructured":"Qin L, Jing X, Qiu Z, Cao W, Jiao Y, Routy J-P, Li T. Aging of immune system: Immune signature from peripheral blood lymphocyte subsets in 1068 healthy adults. Aging (Albany NY). 2016;8:848\u201359. https:\/\/doi.org\/10.18632\/aging.100894.","journal-title":"Aging (Albany NY)"},{"key":"1186_CR18","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s13075-017-1306-0","volume":"19","author":"J Thiel","year":"2017","unstructured":"Thiel J, Rizzi M, Engesser M, Dufner A-K, Troilo A, Lorenzetti R, Voll RE, Venhoff N. B cell repopulation kinetics after rituximab treatment in ANCA-associated vasculitides compared to rheumatoid arthritis, and connective tissue diseases: a longitudinal observational study on 120 patients. Arthritis Res Ther. 2017;19:101. https:\/\/doi.org\/10.1186\/s13075-017-1306-0.","journal-title":"Arthritis Res Ther"},{"key":"1186_CR19","doi-asserted-by":"publisher","first-page":"e200056","DOI":"10.1212\/NXI.0000000000200056","volume":"10","author":"C Starvaggi Cucuzza","year":"2023","unstructured":"Starvaggi Cucuzza C, Longinetti E, Ruffin N, Evertsson B, Kockum I, Jagodic M, Al Nimer F, Frisell T, Piehl F. Sustained Low relapse rate with highly variable B-cell repopulation dynamics with extended rituximab dosing intervals in multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2023;10:e200056. https:\/\/doi.org\/10.1212\/NXI.0000000000200056.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"1186_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v078.i02","volume":"78","author":"C Proust-Lima","year":"2017","unstructured":"Proust-Lima C, Philipps V, Liquet B. Estimation of extended mixed models using latent classes and latent processes: the R package lcmm. J Stat Softw. 2017;78:1\u201356. https:\/\/doi.org\/10.18637\/jss.v078.i02.","journal-title":"J Stat Softw"},{"key":"1186_CR21","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1002\/art.22603","volume":"56","author":"J-O Pers","year":"2007","unstructured":"Pers J-O, Devauchelle V, Daridon C, Bendaoud B, Berre RL, Bordron A, Hutin P, Renaudineau Y, Dueymes M, Loisel S, et al. BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sj\u00f6gren\u2019s syndrome. Arthritis Rheum. 2007;56:1464\u201377. https:\/\/doi.org\/10.1002\/art.22603.","journal-title":"Arthritis Rheum"},{"key":"1186_CR22","doi-asserted-by":"publisher","first-page":"3580","DOI":"10.1002\/art.20592","volume":"50","author":"JH Anolik","year":"2004","unstructured":"Anolik JH, Barnard J, Cappione A, Pugh-Bernard AE, Felgar RE, Looney RJ, Sanz I. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum. 2004;50:3580\u201390. https:\/\/doi.org\/10.1002\/art.20592.","journal-title":"Arthritis Rheum"},{"key":"1186_CR23","doi-asserted-by":"publisher","DOI":"10.1002\/art.42625","author":"T Welte","year":"2023","unstructured":"Welte T, Westermann L, Kappes J, Schramm MA, Bemtgen X, Staudacher DL, Hug MJ, Venhoff N, Arnold F. Identification of covariates modulating B-cell repopulation kinetics in subjects receiving rituximab treatment. Arthritis Rheumatol. 2023. https:\/\/doi.org\/10.1002\/art.42625.","journal-title":"Arthritis Rheumatol"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-023-01186-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-023-01186-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-023-01186-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,16]],"date-time":"2023-12-16T16:18:35Z","timestamp":1702743515000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-023-01186-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,26]]},"references-count":23,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1186"],"URL":"https:\/\/doi.org\/10.1007\/s10238-023-01186-y","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,26]]},"assertion":[{"value":"19 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This is a retrospective study. This study was approved by the Ethics Committee of Peking Union Medical College Hospital (Number: K4038).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}